Macpherson, Iain R.
Spiliopoulou, Pavlina
Rafii, Saeed
Saggese, Matilde
Baird, Richard D.
Garcia-Corbacho, Javier
Italiano, Antoine
Bonneterre, Jacques
Campone, Mario
Cresti, Nicola
Posner, John
Takeda, Yousuke
Arimura, Akinori
Spicer, James
Funding for this research was provided by:
Shionogi (Not applicable)
Article History
Received: 29 January 2019
Accepted: 26 July 2019
First Online: 31 December 2019
Ethics approval and consent to participate
: This study was conducted in accordance with the principles of the International Conference on Harmonisation Good Clinical Practice (ICH GCP) guidelines and the Declaration of Helsinki. The protocol and any accompanying material provided to patients was approved by the London-City and East Research Ethics Committee (14/LO/0641) for patients recruited in the UK and by the Comité de Protection des Personnes Sud-Ouest et Outre Mer III (2014/23) for patients recruited in France.
: Not applicable
: JP undertakes consultancy for and JS has received honoraria from Shionogi & Co., Ltd. Japan. RB undertakes consultancy for and has received travel expense reimbursement from Shionogi Limited UK. SR has received travel expense reimbursement from Shionogi Limited UK. MS is now an employee of AstraZeneca. YT and AA are employees of Shionogi & Co., Ltd. IM has received honoraria and travel expenses from Roche Products UK Ltd. All remaining authors declare that they have no competing interests.